Donafenib after ablation for recurrent liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have liver cancer that has come back for the first or second time.
- The recurrence is within the last year.
- The tumor or tumors are small enough to meet the Milan criteria (a single tumor ≤5 cm, or up to 3 tumors each ≤3 cm).
- Your liver is working well (Child-Pugh A or B) and you are able to care for yourself (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of three drugs (gecacitinib, donafenib, and a PD-1 inhibitor) for people with advanced liver cancer that got worse after initial treatment with immunotherapy. The goal is to see if this 'rechallenge' approach can help control the cancer again.
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
This study tests a new way to treat liver cancer that can't be removed with surgery. It combines a targeted drug (donafenib) with a procedure called E-TACE, which delivers chemotherapy directly to the tumor. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This early-phase study tests whether adding medicines to ablation (heating/freezing to destroy liver tumors) can keep liver cancer from coming back. It’s for people whose liver cancer recurred after prior surgery/ablation but still fits specific criteria, with the goal of improving disease control.
This trial tests a combination of two drugs (donafenib and sintilimab) plus a liver-directed chemotherapy infusion (HAIC) before surgery for liver cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.